Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Presented for research literature review only Vukojevic J et al
Coenzymes enhance the actions of enzymes, helping them to catalyze metabolic reactions
dose-dependent response across 3, 6, and 9 mg arms Phase 3 T2D : HbA1c reductions up to 2.15% versus placebo in Chinese population trials Phase 1b/2 data : Earlier dose-finding studies establishing the efficacy and tolerability profile Global development : Ongoing clinical trials outside China, but no FDA approval or submission as of early 2026 Limitation : Primary clinical data from Chinese population
Do not inject into areas that are tender, bruised, red, hard, or scarred
IGF-1 LR3 is a modified analog designed for extended activity and reduced binding affinity to IGF-binding proteins , allowing prolonged signaling in research models
